Summary:
- GeneEditBio and ToolGen, two biotechnology companies, have entered into a strategic cross-license agreement to accelerate the development of innovative genome-editing therapeutics.
- This agreement allows the companies to share their respective genome-editing technologies, which can be used to treat various genetic disorders and diseases.
- By combining their expertise and resources, GeneEditBio and ToolGen aim to advance the field of genome editing and bring new, effective treatments to patients in need.